You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deal will allow users of MGI's DNBSEQ sequencers to convert previously validated assays to the platform and access Sophia's analytics technology.
The DNBSeq Tx system, several of which are already up and running at the China National GeneBank, can churn out up to 100,000 human genomes per year.
BGI is planning to offer free trials of its MGI DNBSEQ-G400 sequencing system to key opinion leaders, a development Illumina is trying to stop.
The Shenzhen Mammoth Public Welfare Foundation, which BGI sponsors, has also raised funding to purchase PCR and automate sample preparation instruments.
The court dismissed BGI's counterclaim against Illumina for willful infringement of its patent but allowed the claim for induced infringement to proceed.
The new laboratory, which began trial operations this week, is designed to test 10,000 samples per day for the 2019-nCoV coronavirus.
A subsidiary of Curetis, a firm recently merged with OpGen, Ares will use BGI technology to sequence samples in Europe.
The DNBSEQ-T7 ultra-high-throughput sequencer, metagenomic sequencing kit for coronaviruses, and 2019-nCoV RT-qPCR kit have received authorization from China's NMPA.
The researchers also found that the virus was closely related to two bat-derived SARS-like coronaviruses collected in China in 2018.
Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.
A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.
A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.
The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.
In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.